obesity drug news today glp-1 2025 sep 30 The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs A network meta-analysis backed weight-loss

Removing A amyloid plaques is a therapeutic target for Alzheimers disease, as seen in recent market entries like Amgens leqembi and the upcoming approval for donanemab

A possibility for harm reduction As research on GLP-1RAs and AUD advances, it is becoming increasingly clear that these medications have the potential to reduce alcohol consumption

Ozempic Ozempic is another diabetes medication

An analysis of 18 randomized control trials comparing the effects of GLP-1 RAs, SGLT-2 inhibitors, and Metformin demonstrated that semaglutide, dapagliflozin, ipragliflozin, and canagliflozin showed a significant weight loss in comparison with placebo treated controls (6)

19 Given the possibility that existing GLP-1 drugs are insufficient for treating Alzheimers and Parkinsons disease, some researchers are studying new versions of GLP-1s designed to solve that exact problem

While the inflammation-reducing and fibrosis-attenuating effects of glucagon agonism are less well-characterized, the reductions in hepatic inflammation parameters and fibrosis observed in preclinical models likely reflect secondary effects consequent to improved steatosis, rather than direct anti-inflammatory actions [21]